Diffuse large B cell lymphoma (DLBCL) is the most common form of human non-Hodgkin's lymphoma in adults; it accounts for approximately 40% of diagnoses and also arises from the transformation of follicular lymphoma (FL) 1 . Gene-expression profiling studies have identified the heterogeneity of this germinal center (GC)-related malignancy by distinguishing three phenotypic subtypes-GC B cell-like (GCB) DLBCL, activated B cell-like (ABC) DLBCL and primary mediastinal B cell lymphoma 2 -with a small subset of cases that remain unclassified. Those subtypes differ in their genotype, phenotype and, notably, clinical features, including different response to the currently adopted immunochemotherapy-based regimen 3 . Although a subset of patients with DLBCL can be cured, a substantial fraction of them (~40%) die of the disease 3 , which indicates the need to develop more specific targeted therapies.
A r t i c l e s
Diffuse large B cell lymphoma (DLBCL) is the most common form of human non-Hodgkin's lymphoma in adults; it accounts for approximately 40% of diagnoses and also arises from the transformation of follicular lymphoma (FL) 1 . Gene-expression profiling studies have identified the heterogeneity of this germinal center (GC)-related malignancy by distinguishing three phenotypic subtypes-GC B cell-like (GCB) DLBCL, activated B cell-like (ABC) DLBCL and primary mediastinal B cell lymphoma 2 -with a small subset of cases that remain unclassified. Those subtypes differ in their genotype, phenotype and, notably, clinical features, including different response to the currently adopted immunochemotherapy-based regimen 3 . Although a subset of patients with DLBCL can be cured, a substantial fraction of them (~40%) die of the disease 3 , which indicates the need to develop more specific targeted therapies.
Technological advances, including whole-genome sequencing of DNA and RNA and genome-wide copy-number analysis, have provided a comprehensive view of the genomic landscape of GCB DLBCLs and ABC DLBCLs, which has allowed new insights in the genetic lesions associated with the pathogenesis of this malignancy [4] [5] [6] [7] . Such approaches have identified several recurrent lesions that are present in both subtypes of DLBCL, including those involving the functions of chromatin acetylation and methylation, alterations that deregulate the GC master regulator Bcl-6 and those that lead to escape from the immune system 4, 5, [8] [9] [10] . In addition, such studies have confirmed or newly identified genetic lesions 'preferentially' associated with GCB DLBCLs, including chromosomal translocations involving MYC (which encodes the proto-oncoprotein c-Myc) and BCL2 (which encodes the antiapoptotic protein Bcl-2), and mutational activation of EZH2 (which encodes a chromatin-remodeling factor), as well as lesions 'preferentially' associated with ABC DLBCL, including those that lead to activation of the transcription complex NF-κB, translocations involving BCL6 and mutational inactivation of PRDM1 (which encodes Blimp-1, the master regulator of plasma-cell differentiation) [10] [11] [12] [13] [14] [15] [16] .
Among the genetic alterations recurrently found in DLBCL and FL but that remain of unclear functional relevance are mutations affecting MEF2B [4] [5] [6] [7] . MEF2B is a member of the MEF2 ('myocyte enhancerbinding factor 2') family of transcription factors (MEF2A, MEF2B, MEF2C and MEF2D), which are characterized by high homology in their MADS ('MCM1 agamous deficiens SRF') box and an adjacent MEF2 domain 17 . Together those two conserved domains in the amino (N)-terminal half of MEF2B direct DNA binding, homodimerization of MEF2 polypeptides and interaction with specific transcriptional cofactors. The highly divergent carboxy (C)-terminal half of MEF2 proteins has been suggested to modulate their transcriptional activity 17, 18 . The spectrum of targets activated by MEF2 transcription factors in different cell types is dependent on association with specific corepressors and coactivators in response to multiple signaling pathways 17 . In particular, MEF2B functions as a transcriptional activator by binding to specific AT-rich DNA sequences originally identified in the control regions of muscle-specific and growth factorrelated genes 18, 19 . Its activity is regulated by the alternative binding of either the corepressor CABIN1 or class II histone deacetylases to its N terminus, depending on the specific cellular context 20, 21 . MEF2B can express at least two protein isoforms (A and B) with distinct C-terminal domains. In addition, several transcripts, some of which are tissue specific, are generated via alternative splicing. In lymphocytes, MEF2D is involved in T cell antigen receptor-mediated apoptosis and the response to calcium signaling in thymocytes 21, 22 , whereas MEF2C is required for the formation of the GC 23, 24 . In the present study, we identify functional consequences of genetic alterations that affect MEF2B in DLBCLs and FLs and reveal a new role for MEF2B as a master regulator of the GC gene BCL6.
RESULTS

MEF2B mutations in DLBCL and FL
To further investigate the mutations that affect MEF2B in DLBCL and FL, we extended published analyses 4 to include a total of 134 DLBCL samples (111 cases of primary DLBCL and 23 cell lines), as well as 35 cases of primary FL (Fig. 1) . Using genomic PCR amplification and Sanger sequencing of the coding region of MEF2B, we identified 11 sequence variants, distributed in 10 of 134 cases of DLBCL and 1 of 35 cases of FL (Supplementary Table 1 ). We confirmed the somatic origin of the mutations by analysis of paired normal DNA, available in 3 cases from either our own panel or other reported data sets 5, 6 . We verified expression of the mutated MEF2B alleles in cases of primary DLBCL and confirmed the heterozygous nature of the mutations in all mutated DLBCL cell lines. With the exception of a frameshift deletion, all MEF2B mutations affected the two known isoforms (A and B) of MEF2B, both of which are expressed in B cells (Supplementary Table 1 and Supplementary Fig. 1 ).
Including the mutations reported in other studies [5] [6] [7] , most observed variants were missense mutations (69%; 27 of 39), while eight frameshift and four nonsense mutations accounted for the remainder (Fig. 1a) . Most missense mutations (85%) were clustered in the region encoding the N-terminal conserved MADS box and MEF2 functional domains (Fig. 1a) , which suggested that they may affect the transcriptional function of MEF2B. In this region, six amino acid changes of confirmed somatic origin (K4E, K5N, Y69H, E77K, N81Y and D83V) recurrently affected the same codons in distinct cases of DLBCL and FL (Fig. 1a) .
While 81% (73 of 90) of all reported cases with MEF2B mutation had alterations affecting the N-terminal region of MEF2B, a second group of cases (19%; 17 of 90) carried MEF2B mutations that affected the C-terminal half of the protein and included a mixture of frameshift, missense and nonsense mutations and no recurrent events (Fig. 1a) . The nonsense mutations and the majority of frameshift mutations were predicted to generate truncated proteins through deletion of different lengths of the C terminus. Two of those alleles (encoding the substitutions R171X and Y201X) expressed MEF2B proteins with truncation of the C terminus (~19 kilodaltons (kDa) and ~22 kDa, respectively), whereas the frameshift mutations (G242fs, P256fs and L269fs), when expressed as mRNA encoding isoform A, were predicted to generate a full-length protein similar to wild-type isoform B, except for a unique stretch of inserted amino acids ( Supplementary  Fig. 1 ). Collectively, these alleles encoded proteins with truncation of the C terminus or that mimicked the wild-type MEF2B isoform B, which has a distinct C terminus (Supplementary Fig. 1 ). In conclusion, MEF2B was mutated in 7.5% of the cases of DLBCL in our panel, including both GCB DLBCL (7 of 66; 10.6%) and ABC DLBCL (3 of 68; 4.4%), and in 3% of FL cases (1 of 35) (Fig. 1b) .
Induction of MEF2B expression in GC B cells
We investigated the expression pattern of MEF2B in normal mature B cell subpopulations isolated from human tonsils 25 . MEF2B mRNA, but not mRNA encoding other members of the MEF2 family, had abundant expression in GC B cells, with low expression in naive and memory B cells (Fig. 2a) . The expression pattern of MEF2B in these B cell subpopulations was similar to that of the proto-oncogene BCL6 (Fig. 2a,b) , which encodes a transcriptional repressor (Bcl-6) that is selectively expressed in GC B cells of the mature B cell lineage and is required for GC formation and whose deregulated expression is linked to lymphomagenesis 26, 27 . We detected transcripts corresponding to the A and B isoforms of MEF2B in GC B cells (data not shown), and expression of MEF2B protein was high in GC B cells, while it was absent in naive B cells and follicular mantle zones (Fig. 2c,d) . We further confirmed the association of MEF2B expression with the fate of GC B cells in secondary lymphoid tissues of mice challenged with T cell-dependent antigens (Fig. 2e) , in which expression of MEF2B protein appeared in activated B cells soon after immunization (day 2) and slightly preceded that of Bcl-6, a known marker of GC commitment. MEF2B was coexpressed with Bcl-6 throughout the GC reaction, as confirmed by immunofluorescence staining (Fig. 2e and Supplementary Fig. 2a,b) . These observations indicated that MEF2B, like Bcl-6, is a bona fide GC B cell marker.
MEF2B directly regulates BCL6 transcription
The coexpression of MEF2B and Bcl-6 in GC B cells prompted us to investigate the relationship between these two transcription factors. 
A r t i c l e s
Analysis of the 'human B cell interactome' (the entire set of molecular interactions in human B cells) 28 showed that MEF2B was specifically connected to Bcl-6 and the transcription cofactor ZMYND11, which showed positive (Bcl-6) and negative (ZMYND11) transcriptional relationships with MEF2B 29 (Fig. 3a) . Accordingly, MEF2B expression had a strong positive correlation with BCL6 expression in a variety of B cell phenotypes (Fig. 3b) . Moreover, MEF2B seemed to be a main node in the Bcl-6 regulatory network predicted by the ARACNe algorithm, a reverse-engineering approach applied to a large data set of normal and malignant B cells 30 . While MEF2B was not included in the list of direct transcriptional targets bound by Bcl-6 in vivo 31 , we identified several AT-rich DNA sequences resembling canonical MEF2-binding motifs in a ~1.5-kilobase region of the BCL6 promoter proximal to the transcription start site (Supplementary Fig. 2c ), which suggested that MEF2B might bind to the BCL6 promoter region. In support of that hypothesis, chromatin immunoprecipitation (ChIP) analysis of tonsillar GC B cells and two DLBCL cell lines (U2932 and SUDHL4) revealed binding of MEF2B to a region of the BCL6 promoter approximately 1 kilobase upstream of the BCL6 transcription start site ( Fig. 3c and Supplementary Fig. 2c,d) . To determine the transcriptional outcome of the binding of MEF2B to the BCL6 promoter, we analyzed the response to MEF2B of a luciferase reporter gene driven by a native BCL6 promoter region (positions −1593 to −672). Cotransfection of that reporter with increasing amounts of a plasmid expressing wild-type MEF2B in HEK293T human embryonic kidney cells led to a dose-dependent increase in the reporter activity (up to fivefold; Fig. 3d ). While both MEF2B isoforms were able to transactivate the BCL6 reporter construct, isoform B exhibited higher transcriptional activity than did isoform A (Fig. 3d) , both in HEK293T cells and in DLBCL cells (Supplementary Fig. 3) . Deletion of the DNA-binding and dimerization domains of MEF2B or selective mutation of a potential MEF2B consensus site in the promoter region of BCL6 abrogated the ability of MEF2B to transactivate the BCL6 promoter ( Fig. 3d and Supplementary Fig. 3) , which confirmed the specificity of the observed transcriptional effects.
To demonstrate the relevance of the MEF2B-dependent regulation of Bcl-6 expression in vivo, we silenced MEF2B in two DLBCL cell lines (U2932 and SUDHL4) through the use of two different short hairpin RNAs (shRNAs) that target both isoforms of MEF2B. Consistent with the results of the luciferase reporter assays, knockdown of MEF2B led to downregulation of Bcl-6 expression, while knockdown of Bcl-6 did not affect the expression of MEF2B protein or MEF2B mRNA ( Fig. 3e and Supplementary Fig. 4 ). Accordingly, silencing of MEF2B expression in DLBCL cell lines (LY8 and VAL) carrying BCL6 translocations that remove the MEF2B-binding region of the BCL6 promoter did not affect the expression of Bcl-6 protein ( Fig. 3f) , in contrast to results obtained with DLBCL cell lines with wild-type BCL6 alleles (U2932 and SUDHL4; Fig. 3e ). Finally, knockdown of MEF2B in a B cell line (P3HR1) led to increased expression of Bcl-6 target genes 31 ( Supplementary Fig. 4 ). Together these data demonstrated that BCL6 is a direct transcriptional target of MEF2B in normal and malignant GC B cells.
DLBCL proliferation requires MEF2B
To investigate whether, like Bcl-6, MEF2B is required for DLBCL growth, we infected the cell lines SUDHL4 (carrying a MEF2B mutation encoding D83V) and U2932 (carrying wild-type MEF2B) with an inducible lentiviral vector system in which transcription of a cassette encoding the red (orange) fluorescent protein 'turboRFP' (tRFP) and shRNA is dependent on the addition of doxycycline 32 (Fig. 4a) . In SUDHL4 cells, two different shRNAs targeting MEF2B caused a progressive depletion of tRFP + cells, in direct correlation with their ability to decrease the abundance of MEF2B mRNA and MEF2B protein (Fig. 4a,b and Supplementary Fig. 4 ). That growth defect was associated with a substantial decrease in the expression of BCL6 Supplementary Fig. 4 ). As expected, knockdown of Bcl-6 resulted in defective cell growth, with no effect on MEF2B expression ( Fig. 4a,b) . Analysis of cell-cycle distribution by flow cytometry revealed that tRFP + SUDHL4 cells expressing either MEF2B-or Bcl-6-specific shRNA were mainly arrested at the G1 phase of the cell cycle ( Fig. 4c and Supplementary Fig. 4 ), whereas we observed no increase in markers of early apoptosis (annexin V) or cell death (7-AAD; data not shown). We obtained similar results for U2932 cells (data not shown). Enforced expression of Bcl-6 alone was not sufficient to 'rescue' the proliferative defects of B cells after knockdown of MEF2B (Supplementary Fig. 5 ). Therefore, GC-derived lymphoma cells were dependent on MEF2B for their growth and proliferation, and this effect was related only in part to the ability of MEF2B to control Bcl-6 expression.
N-terminal substitutions enhance MEF2B transcriptional activity
We then investigated the consequences of all DLBCL-and FL-associated MEF2B mutations detected in our panel (Supplementary Table 1) , as well as two additional somatic missense mutations (encoding Y69H and N81Y), which are highly recurrent in DLBCL and FL 5 , for their effects on the MEF2B-Bcl-6 transcriptional axis. Analysis of the transcriptional response of the BCL6 promoter to those mutants, through the use of a luciferase reporter assay, showed that a subset of mutations encoding substitutions located in the N-terminal half of MEF2B, including the most recurrent D83V, resulted in increased transcriptional activity ( Fig. 5a and Supplementary Fig. 3 ).
The enhanced transcriptional activity of these mutants suggested a probable dominant effect, as all these MEF2B mutations are present in heterozygous form in cases of primary DLBCL. We confirmed that hypothesis by showing that cotransfection of equimolar amounts of wild-type MEF2B and mutant MEF2B with the D83V substitution, a combination that mimics primary DLBCL, caused an increase in transactivation of the BCL6 promoter similar to that achieved with the D83V MEF2B mutant alone (Supplementary Fig. 6 ).
To confirm the physiological relevance of the findings reported above, we investigated the Bcl-6 transcriptional signature 31 , as a proxy of Bcl-6 activity, in the gene-expression profiles of cases of primary DLBCL 'stratified' by the presence or absence of MEF2B mutations. By gene-set enrichment analysis 33 , we observed that tumors with mutated MEF2B alleles encoding mutant MEF2B with enhanced transcriptional activity showed significant downregulation of Bcl-6 target genes 31 (Fig. 5b) . This result suggested that MEF2B mutants with enhanced transcriptional activity at the BCL6 promoter resulted in increased Bcl-6 biological activity; thus, these may contribute to the deregulation of the proto-oncogene BCL6 in DLBCL and FL. F 20 7  ZN F21 1 ZNF 264  ZNF337  ARID3A  ASH2L BA22A   TS C2 2D 3   TP53   TFE 3 TF DP 1 TC F2 0 A r t i c l e s N-terminal mutants escape CABIN1 corepressor activity To identify the mechanisms by which lymphoma-associated MEF2B mutants affect its transcriptional activity, we used publicly available structural data of the N terminus domain of human MEF2B in complex with DNA and with CABIN1, its known corepressor 20 (Fig. 6a) . We used PyMOL molecular graphics software to study potential structural alterations due to mutant residues and predicted that several MEF2B missense mutations (resulting in the L54P, Y69H, E77K, S78R and D83V substitutions) could impair the ability of MEF2B to bind CABIN1 ( Fig. 6a and Supplementary Table 1) . Additionally, we found that the L38I, L54P and N81Y substitutions could alter the homodimerization of MEF2B, whereas the K4E substitution could affect DNA binding ( Fig. 6a and Supplementary Table 1 ).
To test those predictions, we used coimmunoprecipitation assays to investigate the ability of wild-type and mutant MEF2B to interact with CABIN1 in HEK293T cells transfected to express those two proteins. Six substitutions (L54P, Y69H, E77K, S78R, N81Y and D83V) abrogated the binding of MEF2B to CABIN1, whereas the remaining mutants acted similarly to wild-type MEF2B (Fig. 6b) . Except for N81Y, all the mutants had greater transcriptional activity on BCL6 than did wild-type MEF2B (Fig. 5a) . We confirmed the physiological nature of the interaction between wild-type MEF2B and CABIN1 for endogenous proteins in normal GC B cells and in U2932 and SUDHL10 DLBCL cells (Fig. 6c and Supplementary Fig. 7) . However, that physiological interaction was partially abrogated as a consequence of the heterozygous mutation encoding the D83V substitution present in SUDHL4 and DB DLBCL cells (Fig. 6c and  Supplementary Fig. 7) . We observed no interaction between native wild-type MEF2B and HDAC9 (a class II histone deacetylase reported to interact with MEF2B and other members of the MEF2 family) in GC B cells or DLBCL cell lines (Fig. 6c and Supplementary Fig. 7 ). In agreement with those observations, ChIP assays of a DLBCL cell line that expresses wild-type MEF2B (U2932) confirmed the presence of endogenous CABIN1 at the BCL6 promoter in the MEF2B-bound region (Fig. 6d) . In contrast, MEF2B failed to recruit CABIN1 to the BCL6 promoter in SUDHL4 DLBCL cells (Fig. 6d) , which carry a MEF2B mutation encoding the D83V substitution that abrogated binding to CABIN1 (Fig. 6b,c) . Furthermore, SUDHL4 DLBCL cells had more Bcl-6 protein than did other DLBCL cell lines with similar MEF2B expression (Supplementary Fig. 7b) .
Accordingly, mutant proteins with the L54P, Y69H, E77K, S78R, N81Y or D83V substitution that did not bind CABIN1 in coimmunoprecipitation assays (Fig. 6b,c) or recruit CABIN1 to the BCL6 promoter (Fig. 6d) also escaped the corepression effects of CABIN1 in promoter reporter assays (Fig. 6e) . Reciprocally, an experimentally generated mutation that resulted in the L2172A substitution in CABIN1, which abrogates binding to MEF2B 20 , blocked that corepressive effect ( Supplementary Fig. 7) ; this confirmed the specificity of the MEF2B-CABIN1 interaction. We obtained analogous results for the same mutations in the context of MEF2B isoform A ( Supplementary  Fig. 3 ). An exception to the observations reported above was the L38I mutant, which did not respond to CABIN1 despite its ability to physically interact with this transcriptional corepressor (Fig. 6b,e) . Although the substitution L38I and two other missense mutations (resulting in the L54P and N81Y substitutions) were predicted to affect the dimerization of MEF2B monomers, given the crystal (c) Cell-cycle profiles of tRFP + (+) and tRFP − (−) cell populations at day 2 of coculture as in a; numbers above bars indicate frequency of cells in G1, S or G2-M, detected through the use of the thymidine analog BrdU and staining with 7-AAD (specific phase gates used for quantitation, Supplementary  Fig. 4d,e) . Data are representative of two independent experiments with one cell pool per shRNA. npg structure (Fig. 6a) , we did not observe altered homodimerization in coimmunoprecipitation assays, which suggested that these three mutations may instead result in stabilization of the MEF2B dimer (Supplementary Fig. 8 ). Together these results indicated that a subset of lymphoma-associated MEF2B mutations resulted in abrogation of the binding of MEF2B to CABIN1 and response to its corepressive activity and, consequently, deregulated MEF2B transcriptional activity. Given both the confirmation from biochemical analyses and the structural predictions, this mechanism accounts for 56% of all cases of DLBCL and FL with MEF2B mutations reported thus far (n = 47 of 90 and n = 3 of 90, respectively) 4-6 .
C-terminal mutants escape inactivation by the kinase PKA
The predominance of nonsense and frameshift mutations leading to truncated MEF2B proteins suggested that those mutations may have been selected for the elimination of a C-terminal regulatory domain (Fig. 1a) . That observation, together with the finding that protein kinase A (PKA) phosphorylates the C terminus of MEF2D and abrogates its transactivation activity 34 , prompted us to explore whether MEF2B is similarly regulated by PKA, a serine-threonine protein kinase whose activity is dependent on cytoplasmic concentrations of cyclic AMP 35 .
To investigate whether MEF2B is phosphorylated by PKA in vivo, we metabolically labeled proteins in SUDHL4 DLBCL cells with 32 P in the presence or absence of forskolin (an activator of adenylate cyclase 36 and PKA) and immunoprecipitated MEF2B from those cells (Fig. 7a) . The basal content of phosphorylated endogenous MEF2B was substantially enhanced after the addition of forskolin and was completely blocked in the presence of H89, an established small-molecule inhibitor of PKA 37 ( Fig. 7a) , which indicated the specific involvement of this kinase. We also observed additional bands indicative of phosphorylated highmolecular-weight proteins in the immunoprecipitates (Fig. 7a) , which might correlate with other covalent modifications of MEF2B (such as sumoylation; discussed below). In contrast, mutant MEF2B proteins with the R171X or Y201X substitution (the largest truncated MEF2B proteins) were not phosphorylated in response to treatment with forskolin (Fig. 7b) , which suggested that MEF2B, and more specifically its C terminus, was indeed targeted by PKA-dependent phosphorylation.
To assess the functional consequence of phosphorylation by PKA, we examined its effect on the ability of MEF2B to regulate BCL6 transcription in transient luciferase reporter assays. Similar to published reports of negative regulation of MEF2D by PKA 34 , the transcriptional activity of MEF2B was substantially decreased in the presence of forskolin (Fig. 7c) or exogenous PKA (Fig. 7d) but not in the presence of a 'kinase-dead' PKA mutant (K72H) 38 . Notably, mutant MEF2B with the R171X or Y201X substitution escaped the negative regulation by PKA (Fig. 7c,d) , consistent with the absence of forskolininduced phosphorylation of those mutants (Fig. 7b) . Thus, MEF2B with DLBCL-associated C-terminal truncations disrupted the negative regulatory effects of PKA-dependent phosphorylation.
Frameshift and nonsense mutations abrogate MEF2B sumoylation
In considering the effect of the three frameshift mutations (G242fs, P256fs and L269fs) affecting the most C-terminal portion of the MEF2B protein, we noted that they were predicted to cause the switch from isoform A to isoform B (Supplementary Fig. 1 ). The latter isoform lacks a highly conserved phosphorylation-dependent sumoylation motif (PDSM) 39 found in all members of the MEF2 family (Fig. 8a) . That domain would also be lost in the products of all alleles carrying premature truncating mutations. The PDSM is a bipartite motif composed of a SUMO consensus site (ψKxE, where 'ψ' is a hydrophobic amino acid and 'x' is any amino acid) and a proline-directed phosphorylation site separated from the SUMO site by two amino acids (ψKxExxSP) (Fig. 8a) . To determine whether MEF2B isoform A was sumoylated at the putative Lys319 sumoylation site in the MEF2B PDSM, we assessed whether MEF2B could be modified in vivo in the presence of the small ubiquitinlike modifier SUMO1 and Ubc9, in transient transfection assays. Wild-type isoform A of MEF2B was specifically sumoylated at Lys319, as replacement of that residue with arginine greatly impaired sumoylation; however, isoform B was not sumoylated, as it lacks the PDSM consensus sequence (Fig. 8b) . The shift in the molecular mass of MEF2B by ~15 kDa suggested that MEF2B was modified by monosumoylation at this site (Fig. 8b) . Notably, the serine residue in the PDSM of MEF2B isoform A (Fig. 8a) of that serine residue (Ser324) with alanine greatly impaired both the forskolin-dependent phosphorylation of MEF2B (Fig. 8c) and sumoylation of MEF2B (Fig. 8b) , which suggested that sumoylation of MEF2B was dependent on PKA-mediated phosphorylation at that site in the PDSM consensus. Notably, mutant MEF2B with truncation at the C terminus via either the R171X or Y201X substitution was not sumoylated in the same assay (Fig. 8b) , consistent with the loss of the sumoylation site at position 319. Given that this highly conserved sumoylation motif is not present in isoform B (Fig. 8a) , sumoylation would also be lost in all frameshift mutations predicted to cause the switch from isoform A to B (Supplementary Fig. 1 ).
We then assessed whether that post-translational modification modulated the transcriptional activity of MEF2B, as is the case for other MEF2 proteins 41, 42 . Indeed, sumoylation of MEF2B in the presence of SUMO1 and Ubc9 substantially reduced the transcriptional activity of wild-type MEF2B (Fig. 8d) , whereas substitution of both Lys319 and Ser324 in the PDSM consensus substantially relieved that negative effect on MEF2B activity (Fig. 8d) . The presence of SUMO1 and Ubc9 did not reduce the transcriptional activity of the MEF2B mutants with the DLBCL-associated substitutions R171X and Y201X (Fig. 8d) , consistent with both the loss of the PDSM consensus and the absence of sumoylation on these mutants in vivo (Fig. 8b) .
Together these results showed that phosphorylation-dependent sumoylation negatively regulated the transcriptional activity of MEF2B in B cells. Thus, the majority of lymphoma-associated mutated alleles affecting the C terminus of MEF2B (73%; 11 of 15) escape such negative regulation. Overall, PKA-and sumoylation-mediated regulation of MEF2B is predicted to be lost in ~12% (11 of 90) of all reported cases of DLCBL and FL with mutation of MEF2B [4] [5] [6] .
DISCUSSION
Our results suggest that MEF2B may actually be a hierarchically relevant transcription factor responsible for the initiation of a broad program of gene expression that substantially defines the GC B cell phenotype. Part of this broad MEF2B transcriptional program seems to rely on its ability to modulate the expression of Bcl-6, a key factor in GC biology that modulates the cell cycle, plasma-cell differentiation, responses to DNA damage and antiapoptotic molecules such as Bcl-2 (ref. 26 ). While our results suggest an apical role for MEF2B in 'instructing' the GC phenotype and indicate that Bcl-6 may represent one mediator of its function, additional analyses are needed to comprehensively define the role of this transcription factor in GC formation.
The critical role of MEF2B in the regulation of GC formation is consistent with its targeting by genetic alterations in DLBCL and FL, which represent malignant phenotypes of the GC. Overall, ~11% of cases of DLBCL and 12% of cases of FL 4-6 tested so far carry mutations of MEF2B. Our results indicate that MEF2B mutations have important functional consequences via at least three distinct mechanisms, which differ by the nature and position of the mutations and lead to deregulated MEF2B activity.
The first and most frequent set of mutations affect the N-terminal domain of the protein and represent gain-of-function mutations that enhanced the transcriptional activity of MEF2B by preventing its binding to CABIN1 and by blocking corecruitment of CABIN1 to MEF2B-bound genomic regions. Notably, another member of the MEF2 family, MEF2C, is also targeted by mutations in ~2% of cases of DLBCL 5, 6 ; these mutations affect exclusively the conserved N-terminal MADS box-MEF2 domain known to recruit transcriptional coactivators and corepressors. In fact, residue Tyr69, which is involved in the binding to CABIN1, is also mutant in MEF2C, which suggests a common theme in the selection of mutations of MEF2 family members during B cell lymphomagenesis. However, different from what has been described for the other members of the MEF2 family, we did not detect physical interaction between MEF2B and the coactivator EP300 or its related acetyltransferase molecule CREBBP in coimmunoprecipitation assays (data not shown). Finally, an additional ~26% (23 of 90) of cases with mutant MEF2B, which express MEF2B variants with alteration in the N terminus, probably do not involve the mechanism noted above. For these mutants, alternative mechanisms can be invoked on the basis of structural predictions and published reports; i.e., altered affinity for DNA (predicted for mutations encoding the G2E, K4E, K5E, I8V, R15G and K23V substitutions) or for interactions with basic helix-loop-helix proteins 43 .
A second, less-frequent set of cases have mutations that affect the C terminus of the protein and encode MEF2B proteins still able to bind CABIN1 but with a distinct C terminus due to either truncating nonsense or frameshift mutations or, more rarely, to frameshift mutations that cause the switch from isoform A to the predominant production of isoform B proteins. Such mutations cause MEF2B to escape from PKA-mediated phosphorylation and sumoylation, which probably render MEF2B insensitive to upstream signals of a nature as yet unclear. PKA-mediated phosphorylation of MEF2B may be relevant, given the importance of PKA activity in GC physiology, in which it is required for activation of the cytidine deaminase AID 44, 45 and thus for somatic hypermutation of immunoglobulin-encoding genes and the affinity maturation of antibodies. Therefore, by a different mechanism (i.e., resistance to negative regulatory modifications), the second group of MEF2B mutants (with alterations at the C terminus) may also have deregulated transcriptional activity.
While transcriptional deregulation of BCL6 is probably not the only consequence of aberrant activity of MEF2B, it is clearly a relevant contributor to lymphomagenesis, as shown by the presence of chromosomal translocations that deregulate BCL6 expression in DLBCL and FL 46, 47 and by the demonstration that those events contribute to lymphomagenesis in transgenic mice 48 . Mutational deregulation of MEF2B may represent another mechanism that leads to BCL6 deregulation, as an alternative to those mechanisms reported before, which include aberrant transcriptional regulation by promoter substitution caused by chromosomal translocations 49 , mutations in the BCL6 promoter sequence 16 , defective acetylation in cases with inactivating mutations of CREBBP or EP300 (ref. 8) , or defective ubiquitin-and/or proteasome-mediated degradation due to inactivating mutations of the gene encoding the ubiquitin ligase FBXO11 (ref. 50) . Accordingly, chromosomal rearrangements of BCL6 seem to be mutually exclusive in cases of DLBCL with activating mutations of MEF2B 5 , which supports the idea that both types of lesions act in the same oncogenic pathway.
In conclusion, the functional importance of the large fraction of MEF2B mutations characterized so far suggests their selection for a role in lymphomagenesis. Their distribution in both GCB DLBCL and ABC DLBCL as well as in FL suggests a general role in transformation common to all subtypes. Finally, given the dependence of DLBCL cells on MEF2B for their normal growth and the current efforts to pharmacologically inactivate Bcl-6 (ref. 51) as a targeted strategy for the treatment of these malignancies, the results presented here suggest that MEF2B may represent a therapeutic target for the inhibition of Bcl-6 activity and possibly of a broader GC program to which mature B cell lymphomas may be 'addicted' .
METHODS
Methods and any associated references are available in the online version of the paper. 
